[ad_1]
Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage, near Agen, France March 29, 2018.
Regis Duvignau | REUTERS
Bristol Myers Squibb said on Tuesday it will acquire radiopharmaceutical firm RayzeBio for about $4.1 billion.
Bristol said it will pay $62.50 for each share of RayzeBio in cash, representing a premium of 104% to the stock’s last close.
RayzeBio shares were halted ahead of the deal announcement.
This story is developing. Please check back for updates.
[ad_2]
Source link